Abiomed Invades Underserved Cardiac Markets With Expanded Impella Indications
This article was originally published in Clinica
Executive Summary
Abiomed is asking the US FDA to expand the indication for its Impella family of percutaneous heart pumps to also include patients suffering cardiogenic shock following acute myocardial infarction or cardiac surgery.